$IVVD Cashflow Statement | Understand Stock

$IVVD

$0.59 -$0.02 (3.95%) Close

$IVVD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash acquired in-process research and development
Stock-based compensation expense
Warrant expense
Net amortization of premiums and accretion of discounts on marketable securities
Amortization of operating lease right-of-use assets
Non-Cash Payments
Depreciation Expense
Depreciation and amortization expense
Other non-cash adjustments

Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accrued expenses
Operating lease liabilities
Other current liabilities
Other non-current liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities of marketable securities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs
Proceeds from issuance of common stock, net of commissions and underwriting discounts
Payments of initial public offering costs
Proceeds from exercises of stock options
Proceeds from issuance of common stock under the employee stock purchase plan
Proceeds from issuance of common stock, net of issuance costs
Payments for offering costs
Payments for repurchases of unvested restricted common stock
Proceeds from at-the-market offering, net of commissions
Proceeds from underwritten public offering, net of underwriting discounts and commissions
Payments for at-the-market offering costs
Payments for underwritten public offering costs
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents

Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Operating lease right-of-use asset recognized upon adoption of ASC 842
Operating lease right-of-use asset recognized under ASC 842
Supplemental disclosure of non-cash investing activities:
Issuance of Series A convertible preferred stock in exchange for assigned rights, license and repurchased common stock
Purchases of property and equipment in accounts payable and accrued expenses
Deferred offering costs in accrued expenses
Deferred offering costs in accounts payable
Property and equipment included in accrued expenses
Property and equipment included in accounts payable

Comments